Suchergebnisse - "Minassian, Angela M"

PubPharm (13)

1

Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK : eight-month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2023

von Liu, X. | Munro, A. | Wright, A. | +59

2

Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST) : a multicentre, blinded, phase 2, randomised trial

enthalten in: The Lancet. Infectious diseases | 2022

von Munro, A. | Feng, S. | Janani, L. | +153

CommentIn: Lancet Infect Dis. 2022 Aug;22(8):1092-1093. - PMID 35550263

3

Persistence of immunogenicity after seven COVID-19 vaccines given as third dose boosters following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK : Three month analyses of the COV-BOOST trial

enthalten in: The Journal of infection | 2022

von Liu, X. | Munro, A. | Feng, S. | +56

CommentIn: J Infect. 2023 Feb;86(2):154-225. - PMID 36509358

4

Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002) : a single-blind, randomised, controlled, phase 2/3 trial

enthalten in: Lancet (London, England) | 2021

von Ramasamy, M. | Minassian, A. | Ewer, K. | +162

ErratumIn: Lancet. 2021 Dec 19;396(10267):1978. - PMID 33341142

5

Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST) : a blinded, multicentre, randomised, controlled, phase 2 trial

enthalten in: Lancet (London, England) | 2021

von Munro, A. | Janani, L. | Cornelius, V. | +152

ErratumIn: Lancet. 2021 Dec 18;398(10318):2246. - PMID 34922669

6

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination

enthalten in: Lancet (London, England) | 2021

von Hillson, K. | Clemens, S. | Madhi, S. | +4

7

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil

enthalten in: Nature communications | 2021

von Clemens, S. | Folegatti, P. | Emary, K. | +125

8

Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK : a substudy of two randomised controlled trials (COV001 and COV002)

enthalten in: Lancet (London, England) | 2021

von Flaxman, A. | Marchevsky, N. | Jenkin, D. | +135

CommentIn: Lancet. 2021 Sep 11;398(10304):933-935. - PMID 34480860

9

Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection : a single-arm substudy of a phase 2/3 clinical trial

enthalten in: The lancet. HIV | 2021

von Frater, J. | Ewer, K. | Ogbe, A. | +67

CommentIn: Lancet HIV. 2021 Aug;8(8):e455-e456. - PMID 34153265

10

Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7) : an exploratory analysis of a randomised controlled trial

enthalten in: Lancet (London, England) | 2021

von Emary, K. | Golubchik, T. | Aley, P. | +64

CommentIn: Lancet. 2021 Apr 10;397(10282):1326-1327. - PMID 33798497